#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mantle cell lymphoma stage III Pancreatic carcinoma Fms-like tyrosine kinase 3 positive Breast cancer metastatic Henoch-Schonlein purpura Liposarcoma Pelizaeus-Merzbacher disease Myeloproliferative neoplasm Stevens-Johnson syndrome Inborn error of metabolism ABO haemolytic disease of newborn Ornithine transcarbamoylase deficiency Candida infection Colitis ulcerative Cervix carcinoma More trials…

    Learn about Rare Diseases

    Osteosarcoma – Trials in Disease Short-bowel syndrome – Treatment Myelodysplastic syndrome with excess blasts – Treatment Phenylketonuria – Life with Disease Lymphangioma – Diagnostics Sarcoidosis – Life with Disease Angiosarcoma – Life with Disease Basal cell naevus syndrome – Basic Information Fabry’s disease – Diagnostics Rett syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Doxylamine Hydrogen Succinate Cabazitaxel Clofutriben AMMONIUM (15N) CHLORIDE Eletriptan Rilpivirine Hydrochloride Sodium Oxybate Ataluren Histidine Eftrenonacog Alfa Prasugrel Tng462 Mirodenafil Dihydrochloride Follitropin Delta Fezolinetant Saline Betibeglogene Autotemcel Simeticone Pariglasgene Brecaparvovec Zolbetuximab More therapies…

    Learn about Your Condition

    Retinopathy of prematurity Intestinal ischaemia Corneal graft rejection Fragile X syndrome Hypotransferrinaemia CDKL5 deficiency disorder Splenic marginal zone lymphoma Haemorrhage intracranial Thermal burn Cardiac amyloidosis Implantation complication Arteriosclerosis Encephalopathy neonatal Enteritis Angiosarcoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Chronic lymphocytic leukaemia

  • Study on Acalabrutinib for Very Old or Frail Patients with Chronic Lymphocytic Leukemia

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Acalabrutinib
    Austria Germany

  • Study on the Safety and Effectiveness of Epcoritamab, Venetoclax, and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Epcoritamab
    • Betamethasone Sodium Phosphate
    • Cyclophosphamide
    Belgium Czechia Denmark France Germany Italy +3

  • Study Comparing ACP-196 and Ibrutinib for Patients with High-Risk Chronic Lymphocytic Leukemia

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Acalabrutinib
    • Ibrutinib
    Poland Spain

  • Study of Acalabrutinib for Patients with Chronic Lymphocytic Leukemia

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Acalabrutinib
    Denmark Finland France Germany Italy The Netherlands +3

  • Study on Obinutuzumab and Venetoclax for Elderly Patients with Chronic Lymphocytic Leukemia Unfit for Standard Treatments

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Obinutuzumab
    • Venetoclax
    The Netherlands

  • Study Comparing Pirtobrutinib to Bendamustine and Rituximab for Untreated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Bendamustine Hydrochloride
    • Pirtobrutinib
    • Rituximab
    Austria Bulgaria Czechia France Hungary Italy +4
Previous Page
1 … 8 9 10 11 12 13
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!